Stockscreener 앱 받기
6.29
0.80%
0.05
시간 외 거래:
6.30
0.010
+0.16%
전일 마감가:
$6.24
열려 있는:
$6.24
하루 거래량:
2.12M
Relative Volume:
1.02
시가총액:
$459.12M
수익:
$161.10M
순이익/손실:
$-308.60M
주가수익비율:
-1.3469
EPS:
-4.67
순현금흐름:
$-259.90M
1주 성능:
-15.23%
1개월 성능:
-21.57%
6개월 성능:
-66.36%
1년 성능:
-74.82%
1일 변동 폭
$6.085
$6.29
1주일 범위
$6.055
$7.83
52주 변동 폭
$5.90
$29.61
Arvinas Inc Stock (ARVN) Company Profile
명칭
Arvinas Inc
전화
203-535-1456
주소
395 WINCHESTER AVE, NEW HAVEN, CT
ARVN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
6.29 | 469.33M | 161.10M | -308.60M | -259.90M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-02 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-05-05 | 다운그레이드 | Truist | Buy → Hold |
| 2025-05-02 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-05-02 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-03-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-03-12 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2025-03-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-12-10 | 개시 | BTIG Research | Buy |
| 2024-11-18 | 개시 | Stephens | Overweight |
| 2024-02-28 | 재확인 | Oppenheimer | Outperform |
| 2024-02-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-02-01 | 개시 | Goldman | Buy |
| 2023-12-19 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-11-20 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-10-23 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-01-12 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-01-03 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-09-09 | 개시 | Barclays | Overweight |
| 2022-06-21 | 개시 | Jefferies | Hold |
| 2022-05-09 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-04-28 | 개시 | Credit Suisse | Outperform |
| 2022-04-06 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-02-11 | 재개 | BMO Capital Markets | Outperform |
| 2022-02-10 | 개시 | Wells Fargo | Overweight |
| 2022-01-19 | 개시 | Goldman | Buy |
| 2021-12-07 | 개시 | Cowen | Outperform |
| 2021-10-14 | 개시 | SVB Leerink | Outperform |
| 2021-09-30 | 개시 | Stifel | Buy |
| 2021-09-09 | 개시 | BofA Securities | Buy |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-04-21 | 개시 | Truist | Buy |
| 2021-03-31 | 개시 | BMO Capital Markets | Outperform |
| 2020-12-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2020-06-01 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-05-12 | 개시 | Oppenheimer | Perform |
| 2019-12-19 | 개시 | H.C. Wainwright | Buy |
| 2019-11-25 | 개시 | Guggenheim | Buy |
| 2019-10-24 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-09-25 | 개시 | Wedbush | Outperform |
| 2019-09-12 | 개시 | BMO Capital Markets | Outperform |
| 2019-08-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-06-05 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2018-10-22 | 개시 | Citigroup | Buy |
| 2018-10-22 | 개시 | Goldman | Neutral |
| 2018-10-22 | 개시 | Piper Jaffray | Overweight |
모두보기
Arvinas Inc 주식(ARVN)의 최신 뉴스
Arvinas, Inc. (NASDAQ:ARVN) Shares Acquired by XTX Topco Ltd - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Just Released Its Second-Quarter Earnings: Here's What Analysts Think - 富途牛牛
Pfizer and Arvinas' breast cancer therapy to be reviewed by FDA - MSN
Arvinas (NASDAQ:ARVN) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
FDA Accepts Arvinas, Pfizer's Vepdegestrant NDA for Breast Cancer Treatment - AInvest
FDA to Review Pfizer and Arvinas' Breast Cancer Therapy Vepdegestrant by June 5, 2026. - AInvest
Arvinas' Breakthrough in PROTACs: A Catalyst for Valuation Re-Rating in Oncology's New Frontier - AInvest
Arvinas Q2 2025 Earnings: Revenue Down, Clinical Progress & New CEO Announcement - AInvest
Arvinas, Pfizer announce FDA acceptance of vepdegestrant NDA - TipRanks
Arvinas and Pfizer’s FDA Nod for Cancer Drug - TipRanks
Arvinas and Pfizer Announce FDA Acceptance of NDA for Vepdegestrant Following Positive Phase 3 VERITAC-2 Trial Results in Advanced Breast Cancer - Quiver Quantitative
Arvinas Announces FDA Acceptance of the New Drug - GlobeNewswire
ARVNArvinas Latest Stock News & Market Updates - Stock Titan
HC Wainwright Has Lowered Expectations for Arvinas (NASDAQ:ARVN) Stock Price - MarketBeat
Arvinas (NASDAQ:ARVN) Price Target Cut to $16.00 by Analysts at Wells Fargo & Company - MarketBeat
Guggenheim Cuts Arvinas (NASDAQ:ARVN) Price Target to $15.00 - MarketBeat
Arvinas Holding Company (ARVN) Gets a Buy from Guggenheim - The Globe and Mail
Arvinas Holding’s Strategic Uncertainties and Partnership Challenges Justify Hold Rating - TipRanks
A Quick Look at Today's Ratings for Arvinas(ARVN.US), With a Forecast Between $9 to $18 - 富途牛牛
Arvinas (ARVN) Shares Plunge 2.95% to 2025 Low Amid Mixed Clinical Results and Partnership Uncertainty - AInvest
Arvinas 2025 Q2 Earnings Record Net Income Despite Worsening Losses - AInvest
Arvinas, Pfizer reworking partnership on ‘Protac’ cancer drug - BioPharma Dive
Arvinas signals CEO transition and extends cash runway into H2 2028 amid vepdeg collaboration changes - MSN
Wall Street Has Mixed Opinions On Future Of Arvinas’ Investigational Drug: Retail’s Got A Cautious Approach - Stocktwits
Wedbush Cuts Price Target on Arvinas to $10 From $12, Keeps Neutral Rating - MarketScreener
Arvinas price target raised to $24 from $18 at H.C. Wainwright - TipRanks
Arvinas, Inc. (NASDAQ:ARVN) Q2 2025 Earnings Call Transcript - Insider Monkey
Arvinas (NASDAQ:ARVN) Is In A Good Position To Deliver On Growth Plans - 富途牛牛
Guggenheim lowers Arvinas stock price target to $15 on partnership concerns - Investing.com
Insider Sellers Might Regret Selling Arvinas Shares at a Lower Price Than Current Market Value - simplywall.st
Arvinas Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Arvinas Holding Company: Strong Cash Position and Promising Pipeline Justify Buy Rating - TipRanks
Federated Hermes Inc. Purchases 933,183 Shares of Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas Reports Q2 2025 Financials and Drug Developments - TipRanks
Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Arvinas Earnings Call: Balancing Progress and Challenges - TipRanks
Arvinas Q2 2025 Earnings Call Transcript - MarketBeat
ARVINAS, INC. SEC 10-Q Report - TradingView
Arvinas Holding Company: Hold Rating Amid Modest Data and Strategic Uncertainties - TipRanks
Arvinas shares fall 16.16% intraday after Q2 revenue drops 71% and net loss widens. - AInvest
Earnings call transcript: Arvinas Q2 2025 results show revenue miss, stock drops - Investing.com Canada
Arvinas, Inc. (ARVN) Reports Q2 Loss, Misses Revenue Estimates - sharewise.com
Arvinas earnings beat by $0.10, revenue fell short of estimates - Investing.com Canada
Arvinas Inc (ARVN) Q2 2025 Earnings: EPS Beats Estimates at -$0. - GuruFocus
Arvinas reports Q2 EPS (84c), consensus (89c) - TipRanks
Breakthrough: Arvinas Files Historic First PROTAC Cancer Drug Application, Advances Novel Pipeline - Stock Titan
What To Expect From Arvinas Inc (ARVN) Q2 2025 Earnings - Yahoo Finance
What drives Arvinas Inc. stock priceFind market-beating stocks for your portfolio - Jammu Links News
What are the technical indicators suggesting about Arvinas Inc.Unlock the power of real-time market data - Jammu Links News
Arvinas (NASDAQ:ARVN) Stock Price Up 8.6%Time to Buy? - MarketBeat
Arvinas Inc (ARVN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):